Dry Eye Clinical Trial - Dailies Total 1 Sphere Contact Lenses

Status Completed

Clinical Trial Summary

CL discomfort is a complex phenomenon that has been defined by the Tear Film and Ocular Surface Society in their seminal report on contact lens (CL) discomfort as a condition that results in "episodic or persistent adverse ocular sensation related to lens wear, either with or without visual disturbance resulting from reduced compatibility between the CL and the environment, which can lead to decreased wearing time and discontinuation of CL wear." A recent review by Pucker and Tichenor found that CL discomfort was the top reason for established CL wears to cease wearing CLs. This same review alarmingly found that the frequency of CL dropout was about 20% across the many studies aimed at evaluating this condition, which is surprising given the introduction of better soft CL materials and daily disposable CLs over the past 20 plus years. Dailies Total1 (DT1), which is a relatively new daily disposable CL, is a commonly used trouble shooting CL for patients who have failed with other CLs because DT1 utilizes advanced material technology that is specifically aimed at improving CL comfort. While DT1 is commonly used in these struggling patients, the literature currently lacks a targeted study aimed at understanding the frequency of successfully refitting CL dropouts into this advanced CL. Thus, the purpose of this study is to determine the frequency that past CL wearers who failed because of dryness or CL discomfort who can comfortable wear DT1.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05239494
Study type	Interventional
Source	University of Alabama at Birmingham
Contact
Status	Completed
Phase	N/A
Start date	May 23, 2022
Completion date	August 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05102409` - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease	Phase 2
Completed	`NCT06159569` - Performance and Tolerability of the Medical Device LACRIACT	N/A
Completed	`NCT05027087` - The Effect of a Novel Blueberry Supplement on Dry Eye Disease	Phase 3
Completed	`NCT04081610` - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution	Phase 1
Completed	`NCT05062564` - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye	N/A
Completed	`NCT05825599` - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms	N/A
Completed	`NCT03418727` - Dry Eye Disease Study With Brimonidine	Phase 2
Active, not recruiting	`NCT04425551` - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction	N/A
Recruiting	`NCT04527887` - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)	Phase 4
Not yet recruiting	`NCT06379685` - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.	Phase 1
Active, not recruiting	`NCT05618730` - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B	Phase 1
Completed	`NCT04553432` - Dry Eye OmniLenz Application of Omnigen Research Study	Phase 4
Recruiting	`NCT04109170` - Dry Eye Evaluation System Based on Bioinformatics
Completed	`NCT04105842` - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type	N/A
Completed	`NCT05505292` - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers	Phase 4
Completed	`NCT04668131` - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease	N/A
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Not yet recruiting	`NCT02218827` - Topical Steroid Treatment For Dry Eye	N/A
Completed	`NCT02235259` - Efficacy and Safety of XG-104 for the Treatment of Dry Eye	Phase 2
Completed	`NCT01959854` - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye	N/A